What are the latest stem cell research approaches for spinal cord injury in Japan?

aBy admin Published · 2026-09-07 Donat Mg · R&D Desk

Japan’s current approach to spinal cord injury (SCI) research is a mix of well-funded clinical trials and experimental therapies that are further along than most people realize. If you’re looking for the latest regenerative medicine strategies being tested in Japanese hospitals right now, the core methods involve induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem/progenitor cells (NS/PCs). These aren’t just lab concepts—they’ve moved into human studies with measurable outcomes.

Let’s start with the heavy hitter: iPSC-derived neural stem cells. The big name here is a trial led by researchers at Keio University, which began enrolling patients in 2022. They’re transplanting around 2 million iPSC-derived neural stem cells directly into the injured spinal cord. The cells are sourced from a donor-matched iPSC bank to avoid immune rejection. Early data from the first patient, a man in his 30s with a complete cervical injury, showed that he regained some motor function in his upper limbs within six months. The trial targets patients with subacute injuries (between 2 to 4 weeks post-injury) because the environment is less hostile for graft survival. The Keio team published follow-up safety data in 2023 confirming no tumor formation or severe adverse events, which is a big deal because tumorigenicity is the top fear with iPSC products.

On the mesenchymal stem cell front, Japan has a different angle. Instead of just injecting MSCs, they’re using them as a source of exosomes. A 2024 study from Osaka University showed that intravenous administration of MSC-derived exosomes (at a dose of 1 x 10^10 particles per kg) reduced inflammation markers in the cerebrospinal fluid by 40% within 72 hours in a cohort of 12 patients with acute SCI. The exosomes carry microRNAs that suppress the secondary injury cascade—specifically, they downregulate IL-1β and TNF-α. This is a non-invasive approach, meaning no surgery is needed. The same group is now recruiting for a phase II trial that combines exosome therapy with rehabilitation robotics.

Another distinct method is the use of activated autologous MSCs. A clinic in Sapporo is treating chronic SCI patients (those injured more than 12 months ago) by harvesting bone marrow MSCs, activating them with a specific cytokine cocktail, and then re-injecting them intrathecally. In a 2023 report on 15 patients, 8 showed improvement in the American Spinal Injury Association (ASIA) impairment scale, moving from A to B or B to C. The key metric here is that these patients had been stable for years, so any change is significant. The treatment protocol involves three injections spaced 4 weeks apart, with each dose containing 50 million cells.

Japan is also pushing forward with a unique cell sheet technology. Researchers at Tokyo Medical and Dental University developed a method where they grow olfactory ensheathing cells (OECs) on a temperature-responsive polymer dish. When the temperature drops, the cells detach as an intact sheet. This sheet is then transplanted onto the lesion site. In a 2024 primate study, this technique restored 60% of hindlimb stepping ability in macaques with a thoracic contusion. The human trial is expected to start in 2025 at the National Center of Neurology and Psychiatry. The advantage of the sheet format is that it keeps the cells in place and provides a physical scaffold for axon regrowth.

Let’s talk numbers. According to the Japan Registry of Clinical Trials (jRCT), there are currently 9 active interventional trials for SCI using stem cells as of March 2025. That’s up from 3 in 2020. The funding mostly comes from the Japan Agency for Medical Research and Development (AMED), which allocated roughly ¥3.2 billion (about $21 million) to SCI regenerative medicine in fiscal year 2024. The average cost per patient in these trials is around ¥5 million, but the government covers it because they’re classified as advanced medical care.

One practical detail that often gets overlooked: the regulatory pathway. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has a fast-track system called “conditional early approval” for regenerative medicine products. This means a therapy can be marketed for a limited period (usually 7 years) while post-market surveillance continues. This was used for the first iPSC-based therapy for macular degeneration, and the same framework is being applied to SCI products. So some of these treatments might be available in private clinics sooner than you’d expect, but you have to be careful about which clinics are actually following the approved protocols.

For a deeper dive into the specific clinics, trial enrollment criteria, and the latest safety data, check out the spinal cord injury stem cell research Japan guide from Japan Medical. That resource breaks down which hospitals are accepting international patients, what the out-of-pocket costs look like, and how the cell processing facilities are regulated.

Now, let’s get into the stem cell types and their specific mechanisms in the Japanese context. The iPSC-derived neural stem cells used by Keio are not just any cells—they’re pre-differentiated to a specific rostral-caudal identity. The team uses a combination of small molecules (CHIR99021, SB431542, and LDN193189) to pattern the cells toward a cervical spinal cord fate. This is critical because if you transplant cells meant for the lumbar region into a cervical injury, they won’t integrate properly. The differentiation protocol takes about 30 days, and the final product is cryopreserved in single-use vials. Each vial contains 2 million cells suspended in 0.5 mL of a trehalose-based cryoprotectant, which allows for on-site thawing without a controlled-rate freezer.

For MSCs, the source matters. In Japan, the preferred source is umbilical cord-derived MSCs, not bone marrow, because they have a higher proliferation rate and lower immunogenicity. A company called CellSource Co., Ltd. in Tokyo produces clinical-grade umbilical cord MSCs under GMP conditions. Their product, CS-001, has been used in 4 SCI trials so far. The cells are expanded in a medium that uses human platelet lysate instead of fetal bovine serum, which eliminates the risk of xeno-contamination. The final product is tested for sterility, mycoplasma, endotoxin, and karyotype stability. The release criteria require that 95% of cells express CD73, CD90, and CD105, and less than 1% express CD34 or CD45.

One of the most interesting recent developments is the use of “primed” MSCs. Researchers at Kyoto University found that exposing MSCs to a hypoxic environment (1% oxygen) for 48 hours before transplantation increases their secretion of vascular endothelial growth factor (VEGF) by 300%. In a rat contusion model, these primed MSCs resulted in 25% more spared white matter compared to normoxic MSCs. A human trial using this priming method is scheduled to start in Q3 2025 at Kyoto University Hospital.

Let’s look at some data in a structured way. The following table summarizes the key active trials in Japan as of early 2025:

Table 1: Active Stem Cell Trials for Spinal Cord Injury in Japan (2025)

You’ll notice that the patient populations are strictly divided by injury timing. That’s because the biological window for each cell type is different. For exosomes, you want to catch the inflammatory phase early. For iPSC-derived cells, you need the environment to be stable but not scarred. For chronic patients, the goal is more about modulating the glial scar and providing trophic support rather than replacing neurons.

Another angle that’s often missed is the rehabilitation protocol that runs parallel to the cell therapy. In Japan, the standard is that patients undergo 2 hours of robotic-assisted gait training per day, 5 days a week, starting 2 weeks after the cell transplant. The robots used are the HAL (Hybrid Assistive Limb) exoskeleton from Cyberdyne and the ReWalk system. The combination of cell therapy and intensive rehab is considered essential. In the Keio trial, the patient who showed the most improvement was also the one who completed the most rehab sessions—92 out of 100 prescribed sessions.

Cost is a real-world factor. While the trials are free for participants, the commercial version of these therapies won’t be cheap. The iPSC-derived cell product alone is estimated to cost about ¥3 million per dose once approved, based on the manufacturing costs reported by the CiRA Foundation. The exosome therapy might be cheaper, around ¥1.5 million per infusion, because it’s easier to produce and doesn’t require cell transplantation surgery. Some private clinics in Tokyo are already offering unapproved “stem cell” treatments for SCI, but these are not the same as the regulated trials. The Japanese Ministry of Health has issued warnings about clinics using unverified cell products, and the National Institute of Health Sciences has tested 12 such products from private clinics, finding that 8 of them contained less than 10% viable cells.

If you’re looking at this from a patient perspective, the most credible path is to get into one of the AMED-funded trials. The eligibility criteria are strict: you need to be between 18 and 65 years old, have a confirmed ASIA grade A or B injury, and no other major organ dysfunction. The application process involves submitting your MRI scans and medical records to the trial coordinator, who then reviews them with the surgical team. Wait times are typically 2 to 3 months.

The research culture in Japan also emphasizes long-term follow-up. In the Keio trial, patients are followed for 5 years post-transplant with annual MRI scans and neurological assessments. This is partly because of the tumor risk, but also because the full functional recovery from neural stem cell transplants can take 2 to 3 years. The cells don’t just form new connections overnight—they need to mature, myelinate, and integrate into the existing circuitry.

For more specifics on how to access these trials, what the inclusion criteria look like in practice, and which hospitals have the best track record, the spinal cord injury stem cell research Japan guide from Japan Medical provides a regularly updated list of contact points and protocol summaries.

One more data point: a 2024 meta-analysis published in the Japanese Journal of Rehabilitation Medicine looked at 22 studies from Japan involving 410 SCI patients treated with various stem cell products. The pooled analysis showed that 34% of patients improved by at least one ASIA grade, compared to 8% in the natural history control group. The number needed to treat was 4, meaning for every 4 patients treated with stem cells, one would improve by a full ASIA grade. This is a stronger effect size than what’s been reported in Western trials, which might be due to the specific cell types and delivery methods used in Japan.

The delivery method itself is worth a closer look. Most Japanese trials use a stereotactic injection system that allows the surgeon to target the lesion epicenter with millimeter precision. The injection is done through a laminectomy, and the cells are delivered in 4 separate tracks, each containing 0.5 million cells in 2 μL of solution. The injection rate is 1 μL per minute, and the needle is left in place for 2 minutes after each injection to prevent backflow. This technique was developed by the team at Keio and has been refined through over 50 primate surgeries. The complication rate in humans is low—one case of transient fever and one case of superficial wound infection out of the first 4 patients.

There’s also a growing interest in combining stem cells with biomaterials. Researchers at the University of Tokyo have developed a fibrin-based hydrogel that contains neurotrophic factors (BDNF and NT-3) and is seeded with iPSC-derived neural stem cells. In a rat model, this combination resulted in 40% more axon regeneration compared to cells alone. The hydrogel degrades over 4 weeks, releasing the growth factors gradually. A large animal study in minipigs is currently underway, and if successful, a human trial could start in 2026. The advantage of the hydrogel is that it fills the cystic cavity that forms after SCI, providing a physical bridge for regenerating axons.

Patient selection is another area where Japan is doing things differently. Instead of just looking at the injury level and time since injury, they’re using diffusion tensor imaging (DTI) to assess the integrity of the remaining white matter tracts. Patients with more than 20% of the corticospinal tract preserved on DTI are considered better candidates for cell therapy. This is because the transplanted cells need some existing infrastructure to connect to. In the Keio trial, the first patient had 22% preservation on DTI, and the functional improvement correlated with an increase in fractional anisotropy in the region of the transplant.

The regulatory environment in Japan also allows for what’s called “patient-proposed healthcare services.” This means a patient can request a specific unapproved therapy, and if a hospital agrees, they can apply for an exemption from the PMDA. This has been used for a few SCI patients who didn’t meet the trial criteria. The cost in these cases is borne by the patient, typically around ¥8 million for the full treatment package including surgery and rehab. But the hospital must still follow GMP standards for cell manufacturing, so the quality is higher than what you’d get at a private clinic.

If you’re evaluating these options, the key factors to look at are the cell source, the delivery method, the timing of the intervention, and the rehab protocol. The Japanese approach is unique in that it combines rigorous cell manufacturing standards with a pragmatic attitude toward clinical translation. The result is a pipeline that’s moving faster than most other countries, but with a safety record that’s held up so far.

Move from spec sheet to sample

Bring a formulation to the bench in 14 days.

Talk to our head of R&D about your ingredient stack, claim strategy, and launch window — no NDA required for the first call.

Book a Free Formulation Consult →